RCS is now available on the iPhone as of the latest update, but your carrier still has to support it. These carriers will ...

The latest MVP connectivity foray is food. He has begun producing food big time. Access to food, after all, is the ultimate inclusion. So combine quality yet affordable water, electricity, telephone ...

Intra-Cellular Therapies Inc (ITCI) stock saw a decline, ending the day at $126.2 which represents a decrease of $-0.06 or -0.05% from the prior close of $126.26. The stock opened at $126.65 and ...

Chlorcyclizine shows promise in reducing protoporphyrin-IX accumulation and liver damage in erythropoietic protoporphyria, ...

"Berries offer an exceptional combination of nutrients and compounds that support longevity and healthy aging. They’re ...

High-speed internet is not a luxury—it is a lifeline for economic opportunity. More than $1.3 billion was invested in the BPO ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

Cellular microbiology is the scientific study of the functions and properties of microbial cells. This discipline combines techniques and approaches of classic cell biology and microbiology. The ...

Johnson & Johnson is set to acquire Intra-Cellular Therapies for $14.6 billion to enhance its neuroscience drug portfolio.

S&P Global Ratings placed Johnson & Johnson on CreditWatch with negative implications, citing its nearly $15 billion deal to acquire mental-illness drug developer Intra-Cellular Therapies.

Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...